Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis

Much of the morbidity and mortality due to prostate cancer happen because of castration-resistant prostate cancer (CRPC) which invariably develops after anti-androgenic therapy. FDA-approved enzalutamide is commonly prescribed for CRPC which works by blocking androgen receptor function. However, eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Monga, Jitender, Subramani, Dhatchayini, Bharathan, Ajay, Ghosh, Jagadananda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171151/
https://www.ncbi.nlm.nih.gov/pubmed/32313135
http://dx.doi.org/10.1038/s41598-020-62845-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171151/
https://www.ncbi.nlm.nih.gov/pubmed/32313135
http://dx.doi.org/10.1038/s41598-020-62845-8

Ejemplares similares